Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study
Authors:
Open Access
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialThe Lancet, 2015
- 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancerAnnals of Oncology, 2015
- A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903)Cancer, 2012
- Survival of patients with clinical stage IIIA non–small cell lung cancer after induction therapy: Age, mediastinal downstaging, and extent of pulmonary resection as independent predictorsThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trialThe Lancet, 2009
- The Significance of One-Station N2 Disease in the Prognosis of Patients With Nonsmall-Cell Lung CancerThe Annals of Thoracic Surgery, 2008
- Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancerThe Lancet Oncology, 2008
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2007
- Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II TrialJournal of Clinical Oncology, 2003